Cessatech A/S: peers
Cessatech A/S beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Cessatech A/S, Orphazyme A/S, Niki BioSolutions, Inc., PCI Biotech Holding ASA, Evaxion Biotech A/S, SoftOx Solutions AS, Eurocine Vaccines AB (publ), OncoZenge AB (publ): the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Cessatech A/Sbase 8GN.F · 🇩🇰 DK Percentile in Healthcare Percentile in Denmark | Orphazyme A/S ORPHA.CO · 🇩🇰 DK Percentile in Healthcare Percentile in Denmark | Niki BioSolutions, Inc. NIKI · 🇬🇧 GB Percentile in Healthcare Percentile in UK | PCI Biotech Holding ASA PCIB.OL · 🇳🇴 NO Percentile in Healthcare Percentile in Norway | Evaxion Biotech A/S EVAX · 🇩🇰 DK Percentile in Healthcare Percentile in Denmark | SoftOx Solutions AS SOFTX.OL · 🇳🇴 NO Percentile in Healthcare Percentile in Norway | Eurocine Vaccines AB (publ) 8X4.F · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | OncoZenge AB (publ) ONCOZ.ST · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $4 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one5th of 8 | $7 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $6 Mlast known, Mar 8, 2026 · Market dataLast known value: no current one4th of 8 | $8 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8 | $28 MAug 1, 2026 · Market data1st of 8 | $4 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one5th of 8 | $4 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one5th of 8 | $4 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one5th of 8 | $5 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | —— | $8 MFY2025 · SEConly one with it | —— | —— | —— | $8 M— |
| Net income (Higher is better) | —— | —— | $-1 MFY2025 · SEC1st of 3 | $-2 MFY2024 · ESEF2nd of 3 | $-8 MFY2025 · SEC3rd of 3 | —— | —— | —— | $-2 M3 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | —— | —— | 45December 31, 2025 · Profileonly one with it | —— | —— | —— | 45— |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | ———— | ———— | +125.5%FY2025 · SEConly one with it93rd98th | ———— | ———— | ———— | +125.5%— |
| Margins and returns | |||||||||
| Operating margin (Higher is better) | ———— | ———— | ———— | ———— | -122.6%FY2025 · SEConly one with it21st6th | ———— | ———— | ———— | -122.6%— |
| Net margin (Higher is better) | ———— | ———— | ———— | ———— | -102.4%FY2025 · SEConly one with it22nd6th | ———— | ———— | ———— | -102.4%— |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | ———— | -88.0%FY2025 · SEConly one with it23rd7th | ———— | ———— | ———— | -88.0%— |
| Return on equity (Higher is better) | ———— | ———— | -6.2%FY2025 · SEC1st of 369th20th | -51.8%FY2024 · ESEF2nd of 343rd9th | -100.2%FY2025 · SEC3rd of 325th5th | ———— | ———— | ———— | -51.8%3 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 3.7׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | —— |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 1.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | —— |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | ———— | -23.7%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | —— |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | 0.3×FY2025 · SEConly one with it39th— | ———— | ———— | ———— | 0.3×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | 0 of 8FY2025 · Scorecard2nd of 3 | 0 of 2FY2024 · Scorecard2nd of 3 | 4 of 9FY2025 · Scorecard1st of 3 | —— | —— | —— | 0% passed3 ranked |
| Growth checks (Higher is better) | —— | —— | 0 of 2FY2025 · Scorecard2nd of 2 | —— | 2 of 2FY2025 · Scorecard1st of 2 | —— | —— | —— | 50% passed2 ranked |
| Profitability checks (Higher is better) | —— | —— | 0 of 3FY2025 · Scorecard1st of 3 | 0 of 2FY2024 · Scorecard1st of 3 | 0 of 4FY2025 · Scorecard1st of 3 | —— | —— | —— | 0% passed3 ranked |
| Financial health checks (Higher is better) | —— | —— | 0 of 2FY2025 · Scorecard2nd of 2 | —— | 2 of 3FY2025 · Scorecard1st of 2 | —— | —— | —— | 33% passed2 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | 0 of 1FY2025 · Scorecardonly one with it | —— | —— | —— | —— | —— | 0% passed— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cessatech A/S: How market caps are worked out; Orphazyme A/S: How market caps are worked out; Niki BioSolutions, Inc.: How market caps are worked out; PCI Biotech Holding ASA: How market caps are worked out; Evaxion Biotech A/S: How market caps are worked out; SoftOx Solutions AS: How market caps are worked out; Eurocine Vaccines AB (publ): How market caps are worked out; OncoZenge AB (publ): How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Cessatech A/S | — | — | — |
| Orphazyme A/S | — | — | — |
| Niki BioSolutions, Inc. | — | — | — |
| PCI Biotech Holding ASA | — | — | — |
| Evaxion Biotech A/S | -122.6%FY2025 | 21st percentile in Healthcaremedian -7.7%, 674 companies | 6th percentile in Denmarkmedian -4.5%, 26 companies |
| SoftOx Solutions AS | — | — | — |
| Eurocine Vaccines AB (publ) | — | — | — |
| OncoZenge AB (publ) | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
| Fiscal year | Cessatech A/S | Orphazyme A/S | Niki BioSolutions, Inc. | PCI Biotech Holding ASA | Evaxion Biotech A/S | SoftOx Solutions AS | Eurocine Vaccines AB (publ) | OncoZenge AB (publ) |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | — | $8 MSEC | — | — | — |
| 2024 | — | — | — | — | $3 MSEC | — | — | — |
| 2023 | — | — | $0 MSEC1st | — | $0 MSEC2nd | — | — | — |
| 2022 | — | — | $1 MSEC | — | — | — | — | — |
| 2021 | — | — | $2 MSEC | — | — | — | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Cessatech A/S#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Orphazyme A/SORPHA.CO · 🇩🇰 DenmarkSame industry: Biotechnology · Similar size: $7 M market cap against $4 M · Same country: DenmarkMarket cap $7 M (last known, Jan 5, 2024) · revenue $0 M (year to December 2020)91 of 100 (industry or sector 50 + size 26 + country 15)In the group
- Niki BioSolutions, Inc.NIKI · 🇬🇧 UKSame industry: Biotechnology · Similar size: $6 M market cap against $4 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $6 M (last known, Mar 8, 2026)89 of 100 (industry or sector 50 + size 27 + country 7 + figures on file 5)In the group
- PCI Biotech Holding ASAPCIB.OL · 🇳🇴 NorwaySame industry: Biotechnology · Similar size: $8 M market cap against $4 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $8 M (last known, Jan 5, 2024)88 of 100 (industry or sector 50 + size 26 + country 7 + figures on file 5)In the group
- Evaxion Biotech A/SEVAX · 🇩🇰 DenmarkSame industry: Biotechnology · 7.0× larger by market cap · Same country: Denmark · Ratios of the last two fiscal years on fileMarket cap $28 M (Aug 1, 2026) · revenue $8 M (year to December 2025)87 of 100 (industry or sector 50 + size 17 + country 15 + figures on file 5)In the group
- SoftOx Solutions ASSOFTX.OL · 🇳🇴 NorwaySame industry: Biotechnology · Similar size: $4 M market cap against $4 M · Same region: Northern EuropeMarket cap $4 M (last known, Jan 5, 2024)87 of 100 (industry or sector 50 + size 30 + country 7)In the group
- Eurocine Vaccines AB (publ)8X4.F · 🇸🇪 SwedenSame industry: Biotechnology · Similar size: $4 M market cap against $4 M · Same region: Northern EuropeMarket cap $4 M (last known, Dec 25, 2022)87 of 100 (industry or sector 50 + size 30 + country 7)In the group
- OncoZenge AB (publ)ONCOZ.ST · 🇸🇪 SwedenSame industry: Biotechnology · Similar size: $4 M market cap against $4 M · Same region: Northern EuropeMarket cap $4 M (last known, Jan 5, 2024)87 of 100 (industry or sector 50 + size 30 + country 7)In the group
- Biosergen ABBIOSGN.ST · 🇸🇪 SwedenSame industry: Biotechnology · Similar size: $4 M market cap against $4 M · Same region: Northern EuropeMarket cap $4 M (last known, Jan 5, 2024)87 of 100 (industry or sector 50 + size 30 + country 7)+ Add
- Forward Pharma A/S1FPB.F · 🇩🇰 DenmarkSame industry: Biotechnology · Similar size: $14 M market cap against $4 M · Same country: DenmarkMarket cap $14 M (last known, Dec 25, 2022)87 of 100 (industry or sector 50 + size 22 + country 15)+ Add
- CombiGene AB (publ)COMBI.ST · 🇸🇪 SwedenSame industry: Biotechnology · Similar size: $5 M market cap against $4 M · Same region: Northern EuropeMarket cap $5 M (last known, Jan 5, 2024)86 of 100 (industry or sector 50 + size 29 + country 7)+ Add
- Scandinavian ChemoTech AB (publ)CMOTEC-B.ST · 🇸🇪 SwedenSame industry: Biotechnology · Similar size: $5 M market cap against $4 M · Same region: Northern EuropeMarket cap $5 M (last known, Jan 5, 2024)86 of 100 (industry or sector 50 + size 29 + country 7)+ Add
- Nabriva TherapeuticsNTY.F · 🇮🇪 IrelandSame industry: Biotechnology · Similar size: $5 M market cap against $4 M · Same region: Northern EuropeMarket cap $5 M (last known, Jul 30, 2023)86 of 100 (industry or sector 50 + size 29 + country 7)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.